	<u>_</u>	Inaudited Financial results by companies other than banks					
	Particulars	3 Months ended 31.12.2016	Preceeding 3 months ended 30.09.16	Corresponding 3 months ended 31.12,2015	Year to date figures current period ended 01.04.2016 to 31.12.2016	Previous year ended 2015-16	
	(Refer Notes Below	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	1 Income from Operations				,,	(Addited)	
	(a) Net sales/income from operation (Net of excise duty) (b) Other operating income			-	-	- ,	
	Total income from operations (net)	150,000.00	100,000.00	-	450,000.00	600,328.00	
2	Expenses	150,000.00	150,000.00		450,000.00	600,328.00	
1	(a) Cost of materials consumed	_					
1	(b) Purchase of stock-in-trade	_		-		-	
	© Changes in inventories of finished goods, work-in-		ļ	-	-	-	
	progress and stock-in-trade (d) Employee benefits expense	-] - [- 1			
	(e) Depreciation and amortisation expense	-		- 1		-	
i .	(f) Other expenses (Any item exceeding 10% of the total	<u> </u>				.	
	expenses relating to continuing operations to be shown		1				
	separately)	183,719.00	140 700 00			1	
	Total expenses		140,706.00	60,632.00	431,343.00	486,018.00	
3	Profit/(Loss) from operations before other income,	183,719.00	140,706.00	60,632.00	431,343.00	486,018.00	
	finance costs and exceptional items (1-2)	(33,719.00)	9,294.00	(60,632.00)	18,657.00	114,310.00	
İ	Other income	-	-	-	-	-	
3	Profit/ (Loss) from ordinary activities before finance costs and exceptional (3(+ /-)4)	(33,719.00)	9,294.00	(60,632.00)	18,657.00	114,310.00	
6	Finance costs	-	-				
7 F	Profit / (Loss) from ordinary activities after flance costs out before exceptional items (5(+/-)6)	(33,719.00)	9,294.00	(60,632.00)	18,657.00		
8 E	exceptional items	-			10,037.00	114,310.00	
9 P	Profit / (Loss) from ordinary activities before tax (7(+/-	(33,719.00)	9,294.00	(60,632.00)	18,657.00	114 240 00	
10 T	ax expense		-		70,007.00	114,310.00	
11 N)1	let Profit / (Loss) from ordinary activities after tax (9(+/- LO)	(33,719.00)	9,294.00	(60,632.00)	40.05		
12 E	xtraordinary items (net of expense Rs Lakhs)	-	-	(00,032.00)	18,657.00	114,310.00	
13 N	et Profit / (Loss) for the period (11(+/-)12)	(33,719.00)	9,294.00	(60,632.00)	10.057.0	-	
14 Sh	nare of profit / (Loss) of associates*	_		(00,032.00)	18,657.00	114,310.00	
15 M	inority interest*	_	_	-	•	•	
16 Ne	et Profit / (Loss) after taxes, minority interest and						
sh	are of profit / loss of associates (13(+/-)14(+/-)15)*	(33,719.00)	9,294.00	(60,632.00)	18,657.00	114,310.00	
ĺ	id-up equity share capital (Face Value Rs 10)	37,413,000.00	37,413,000.00	44,545,500.00	37,413,000.00	37,413,000.00	
she	serve excluding Revaluation Reserves as per balance eet of previous accounting year	1,144,678.00	1,144,678.00	948,091.00	1,146,678.00	1,128,020.00	
(of (a)	mings per share (before extraordinary items) f Rs/- each) (not annualised): Basic	-	_				
	Diluted				-	•	
(of (a) (nings per share (after extraordinary items) Rs						
	Diluted anying note to the financial results		-	-	-	X PHAP	

* Applicble in the case of consolidated results

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956. Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

- 1 The above financial results have been reveiwed by the Audit Committee and approved by the Board of Directors at the meeting held on 07.02.2017.
- 2 There were no investors complaints during the quarter ended 31st December 2016

 $\ensuremath{\mathtt{3}}$ Previous years figures has been regroup / rearranged wherever necessary.

Place Hadamtala (Rajkot) Date: 07.02.2017

PARMAX PHARMA LIMITED

HADAMTAL

Select Information for the Quarter End 31.12.2016

	Particulars	3 months ended 31.12.16	Preceding 3 months ended 30.09.16	Corresponding 3 months ended 31.12.15	Year to date figures for current period ended 01.04.16 to 31.12.16	Previous year ended 2015-16
Α	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	Number of shares	2650550	2650550	4010050	2650550	2650550
	Percentage of shareholding	70.85%	70.85%	78.62%	70.85%	70.85%
2	Promoters and Promoter Group Shareholding **					
	a) Pledged / Encumbered	Nil	Nil	Nil	Nil	Nil
	Number of shares					
	Percentage of shares (as a % of the total shareholding					
	of promoter and promoter group	Nil	Nil	Nil	Nil	Nil
	Percentage of shares (as a % of the total share capital					
	of the company)	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered					
	Percentage of shares (as a % of the total shareholding					
	of promoter and promoter group	29.15%	29.15%	21.38%	29.15%	29.15%
	Percentage of shares (as a % of the total share capital					
l	of the company)	100%	100%	100%	100%	100%

	Particulars	3 months ended 31.12.2016
В	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
l	Disposed of during the quarter	Nil
	Ramaining unresolved at the end of the quarter	Nil

Note:

- The above results were reviewed by an Audit Committee and thereafter taken on record by the Board of Directors in their meeting held on 07.02.2017.
- There were no investor complaints known to the Company outstanding at the beginning of the quarter.
- Previous period figures have been regrouped wherever necessary.
- Any other notes to be added.



BHARAT A. SHAH

B.Com. F.C.A. (DISA)

B. A. SHAH ASSOCIATES

Chartered Accountants

209 Sapphire, 2nd Floor, 21/25 – B ,New Jagnath Plot, Rajkot. – 360 001. Ph.: 0281 - 2468261

Auditor's Limited Review Report

On Unaudited Financial Results

То

The Board of Directors,
Parmax Pharma Limited

We have reviewed the accompanying statement of unaudited financial results of **PARMAX PHARMA LIMITED** for the quarter ended on **31**st **December 2016**. This statement is the responsibility of the Company's Management.

A review of the interim financial information consist principally of applying analytical procedures for the financial data and making enquiries of persons responsible for financial and accounting matters. It is substantially less in scope than audit conducted in accordance with the generally accepted auditing standards, The objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly we do not express such an opinion. Further our review was mainly in regards to the figures of quarter ended 31st December 2016

During our review we have noticed that:

There are small differences between amounts as per published results and corresponding figured as per the accounts (which are however within tile allowed limit of 10% or Rs. 10 lacs, whichever is higher)

Except this nothing has come to our notice that causes us to believe that the accompanying statements of unaudited financial results have not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed or that it contain any material misstatement.

For B A SHAH ASSOCIATES

Chartered Accountants

Bhut A Shah

FRN.: 109493W

BHARAT SHAH

PROPRIETOR

M. NO.034222

Date: 21.01.2017

Place: Rajkot